UY27341A1 - Formulación farmacéutica de sabor enmascarado y procedimiento para su preparación. - Google Patents

Formulación farmacéutica de sabor enmascarado y procedimiento para su preparación.

Info

Publication number
UY27341A1
UY27341A1 UY27341A UY27341A UY27341A1 UY 27341 A1 UY27341 A1 UY 27341A1 UY 27341 A UY27341 A UY 27341A UY 27341 A UY27341 A UY 27341A UY 27341 A1 UY27341 A1 UY 27341A1
Authority
UY
Uruguay
Prior art keywords
preparation
pharmaceutical formulation
procedure
well
masked
Prior art date
Application number
UY27341A
Other languages
English (en)
Spanish (es)
Inventor
Becourt Philippe
Chauvin Josiane
Schwabe Detlev
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of UY27341A1 publication Critical patent/UY27341A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UY27341A 2001-06-21 2002-06-18 Formulación farmacéutica de sabor enmascarado y procedimiento para su preparación. UY27341A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0108157A FR2826274B1 (fr) 2001-06-21 2001-06-21 Formulation pharmaceutique au gout masque et son procede de preparation

Publications (1)

Publication Number Publication Date
UY27341A1 true UY27341A1 (es) 2003-01-31

Family

ID=8864587

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27341A UY27341A1 (es) 2001-06-21 2002-06-18 Formulación farmacéutica de sabor enmascarado y procedimiento para su preparación.

Country Status (41)

Country Link
US (2) US7138138B2 (OSRAM)
EP (1) EP1401397B1 (OSRAM)
JP (1) JP4880871B2 (OSRAM)
CN (1) CN1239149C (OSRAM)
AP (1) AP1595A (OSRAM)
AR (1) AR036096A1 (OSRAM)
AT (1) ATE290366T1 (OSRAM)
AU (1) AU2002329311B2 (OSRAM)
BG (1) BG66314B1 (OSRAM)
BR (1) BRPI0208998A2 (OSRAM)
CA (1) CA2452239C (OSRAM)
CO (1) CO5540278A2 (OSRAM)
CZ (1) CZ299947B6 (OSRAM)
DE (1) DE60203178T2 (OSRAM)
EA (1) EA006016B1 (OSRAM)
EC (1) ECSP034915A (OSRAM)
ES (1) ES2236574T3 (OSRAM)
FR (1) FR2826274B1 (OSRAM)
GT (2) GT200200115AA (OSRAM)
HR (1) HRP20031067B1 (OSRAM)
HU (1) HUP0400799A3 (OSRAM)
IL (2) IL159404A0 (OSRAM)
JO (1) JO2325B1 (OSRAM)
MA (1) MA27042A1 (OSRAM)
MX (1) MXPA03011756A (OSRAM)
MY (1) MY134340A (OSRAM)
NO (1) NO332258B1 (OSRAM)
NZ (1) NZ530042A (OSRAM)
OA (1) OA12635A (OSRAM)
PA (1) PA8548301A1 (OSRAM)
PE (1) PE20030201A1 (OSRAM)
PL (1) PL202090B1 (OSRAM)
PT (1) PT1401397E (OSRAM)
SK (1) SK285865B6 (OSRAM)
SV (1) SV2003001098A (OSRAM)
TN (1) TNSN03141A1 (OSRAM)
TW (1) TWI228049B (OSRAM)
UA (1) UA77960C2 (OSRAM)
UY (1) UY27341A1 (OSRAM)
WO (1) WO2003000225A2 (OSRAM)
ZA (1) ZA200309479B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
GB2419094A (en) * 2004-10-12 2006-04-19 Sandoz Ag Pharmaceutical composition of unpleasnt tasing active substances
FR2882522B1 (fr) * 2005-02-25 2007-04-13 Aventis Pharma Sa Composition pharmaceutique solide comprenant de la telithromycine
US7384922B2 (en) * 2005-05-04 2008-06-10 Enanta Pharmaceuticals, Inc. 6-11 bridged oxime erythromycin derivatives
US20060264386A1 (en) * 2005-05-17 2006-11-23 Rongqi Sun Pharmaceutical formulations of 6-11 bicyclic ketolide derivatives and related macrolides and methods for preparation thereof
US20090011007A1 (en) * 2006-02-03 2009-01-08 Evonik Roehm Gmbh Pharmaceutical Compositions Containing Mixtures of Polymers and Active Agents Poorly Soluble in Water
WO2007108010A2 (en) * 2006-03-21 2007-09-27 Jubilant Organosys Limited Taste masked pharmaceutical composition for oral solid dosage form and process for preparing the same using magnesium aluminium silicate
US20080181932A1 (en) * 2007-01-30 2008-07-31 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
KR100935893B1 (ko) * 2007-09-11 2010-01-07 국방과학연구소 1,1'-다이메틸-5,5’-바이테트라졸의 합성방법
CA2703475A1 (en) 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
DK2379635T3 (en) 2008-12-16 2016-12-05 Carlsberg As Cellulosic polymer material
KR20140139083A (ko) 2012-03-27 2014-12-04 셈프라 파마슈티컬스, 인크. 마크롤라이드계 항생제를 투여하기 위한 비경구 제제
DE102012014848A1 (de) * 2012-07-27 2012-10-31 Heilerde-Gesellschaft Luvos Just GmbH & Co. KG Heilerde-Zubereitung
AU2015301154A1 (en) * 2014-08-05 2017-02-23 Cempra Pharmaceuticals, Inc. Powder oral suspension formulations of antibacterial agents
US10982177B2 (en) 2017-09-18 2021-04-20 The Clorox Company Cleaning wipes with particular lotion retention and efficacy characteristics
CN114209661B (zh) * 2022-02-21 2022-04-29 北京罗诺强施医药技术研发中心有限公司 呈细粒形式的固体药物组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2930409A1 (de) * 1979-07-26 1981-02-12 Bayer Ag Spruehtrocknung von mikrokapseldispersionen
JPS63150220A (ja) * 1986-12-15 1988-06-22 Dainippon Pharmaceut Co Ltd 経口用固形製剤の製造方法
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
ZA945944B (en) * 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
US6153220A (en) * 1997-10-03 2000-11-28 Elan Corporation, Plc Taste-masked formulations
IN191239B (OSRAM) * 1999-06-11 2003-10-11 Ranbaxy Lab Ltd
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6740642B2 (en) * 2000-08-22 2004-05-25 Basilea Parmaceutica Ag Macrolides with antibacterial activity

Also Published As

Publication number Publication date
OA12635A (fr) 2006-06-15
EA006016B1 (ru) 2005-08-25
CZ299947B6 (cs) 2009-01-07
EP1401397B1 (fr) 2005-03-09
EP1401397A2 (fr) 2004-03-31
PA8548301A1 (es) 2003-09-05
IL159404A (en) 2007-08-19
HUP0400799A3 (en) 2012-08-28
PL366803A1 (en) 2005-02-07
BRPI0208998A2 (pt) 2017-06-06
CZ20033441A3 (en) 2004-03-17
WO2003000225A3 (fr) 2003-03-13
GT200200115AA (es) 2005-01-12
IL159404A0 (en) 2004-06-01
TWI228049B (en) 2005-02-21
CA2452239C (fr) 2011-07-19
GT200200115A (es) 2003-02-27
ECSP034915A (es) 2004-02-26
PL202090B1 (pl) 2009-06-30
ZA200309479B (en) 2005-04-26
DE60203178T2 (de) 2006-01-26
JP2004534810A (ja) 2004-11-18
HRP20031067B1 (en) 2011-10-31
UA77960C2 (en) 2007-02-15
US7138138B2 (en) 2006-11-21
PE20030201A1 (es) 2003-03-12
DE60203178D1 (de) 2005-04-14
PT1401397E (pt) 2005-05-31
MXPA03011756A (es) 2004-07-01
ES2236574T3 (es) 2005-07-16
HRP20031067A2 (en) 2004-04-30
JP4880871B2 (ja) 2012-02-22
JO2325B1 (en) 2006-06-28
TNSN03141A1 (fr) 2005-12-23
SK285865B6 (sk) 2007-10-04
HK1067558A1 (en) 2005-04-15
AP1595A (en) 2006-04-12
WO2003000225A2 (fr) 2003-01-03
ATE290366T1 (de) 2005-03-15
AP2003002927A0 (en) 2003-12-31
NO20035581D0 (no) 2003-12-15
FR2826274B1 (fr) 2003-09-26
CO5540278A2 (es) 2005-07-29
US20070014857A1 (en) 2007-01-18
US20040142029A1 (en) 2004-07-22
MA27042A1 (fr) 2004-12-20
BG108458A (bg) 2005-02-28
MY134340A (en) 2007-12-31
SV2003001098A (es) 2003-03-18
CN1239149C (zh) 2006-02-01
SK15922003A3 (sk) 2004-05-04
FR2826274A1 (fr) 2002-12-27
AR036096A1 (es) 2004-08-11
BG66314B1 (bg) 2013-04-30
NZ530042A (en) 2005-09-30
CN1529585A (zh) 2004-09-15
NO332258B1 (no) 2012-08-13
EA200400061A1 (ru) 2004-06-24
AU2002329311B2 (en) 2007-02-01
CA2452239A1 (fr) 2003-01-03
HUP0400799A2 (hu) 2004-08-30

Similar Documents

Publication Publication Date Title
UY27341A1 (es) Formulación farmacéutica de sabor enmascarado y procedimiento para su preparación.
BR0112495A (pt) Forma de dosagem, processo para a produção de uma forma de dosagem e uso da forma de dosagem
AR082579A2 (es) Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
CR9704A (es) Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma.
NO20075136L (no) Nye liposompreparater
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
AR027091A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
MXPA05007643A (es) Metodo para producir una forma farmaceutica oral con desintegracion inmediata y liberacion de ingrediente activo.
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
WO2003035051A3 (en) The use of proton sequestering agents in drug formulations
MX2009003030A (es) Forma galenita para la administracion por via transmucosa de principios activos.
NO20023551D0 (no) Ibuprofen-inneholdende aktivt middel-preparat
AR034517A1 (es) Formulacion farmaceutica
ATE541562T1 (de) Ibuprofen-suspension
AR048050A1 (es) Formas de administracion masticables, no comprimidas, dosificadas individualmente
AR031649A1 (es) Composicion farmaceutica de dronedarona para administracion parenteral
BR0009927B1 (pt) mÉtodo para produzir uma matriz de liberaÇço controlada, amàrfica ou parcialmente amàrfica insolével em Água.
AR023138A1 (es) Composicion para gomas de mascar medicadas, proceso de fabricacion y tabletas obtenidas con dicho proceso
WO2008087323A3 (fr) Forme galenique pour l'administration par voie trans-muqueuse de paracetamol
MX2021008248A (es) Composicion farmaceutica.
PE20050443A1 (es) Formulaciones farmaceuticas transdermicas
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150826